Iliad Biotechnologies announced that it has raised $115 million in a Series B financing to support continued development of the company’s BPZE1 intranasal vaccine against pertussis (whooping cough). The company said that it intends to initiate a pivotal challenge study of the vaccine this year and expects topline data to be available in 2027. In 2023, Iliad reported positive results from a Phase 2b challenge trial of BPZE1.
Iliad licensed the pertussis vaccine from French research institute Inserm in 2014. BPZE1 received Fast Track designation from the FDA in January 2022 and Innovation Passport designation from the MHRA in 2024.
Iliad CEO Keith Rubin commented, “Today’s financing reflects the urgent need for better pertussis vaccines, the scientific rigor and operational discipline of our team, and the extraordinary potential BPZE1 holds to improve global public health. We are grateful to RA Capital for their diligent efforts to lead the round, to Janus and BNPP AM Alts for their active partnership during the financing process, and to existing investors and all those who came before in support of our mission to eradicate pertussis disease once and for all.”
Read the Iliad Biotechnologies press release
